AI in Drug Development for Pharmacists

Debi Hudgens, PhD, MBA, CLP, CA-AM, is a poignant example of how AI is reshaping the landscape of drug development, especially concerning rare diseases. Diagnosed with a rare renal disease, Hudgens’s passion for helping others in similar situations has driven her to pursue a Master’s in Artificial Intelligence for Drug Development (AIDD) at the University of Maryland School of Pharmacy (UMSOP). This innovative program, crafted by industry experts, aims to equip students with cutting-edge skills in machine learning and natural language processing to enhance drug development efficiency.

Addressing the Need in Rare Diseases

With one in ten Americans afflicted by a rare disease—most notably in children—it is concerning that fewer than 5% of over 10,000 known rare diseases have available treatments. This scenario highlights the pressing need for advancements in drug development. Hudgens voices a critical desire to contribute to areas such as early discovery and translational science, focusing on finding new biomarkers and optimizing clinical trials for these underserved patient populations.

The Role of AI in Drug Development

Experts like Joga Gobburu, PhD, emphasize the potential of AI to enhance drug development by tackling the overwhelming volume of regulatory documents and that drug developers often face. According to Gobburu, AI has the ability to sift through millions of documents to provide precise answers, thereby significantly reducing the burdensome search traditionally undertaken by developers. This capability transforms what was once seen as an insurmountable task into manageable work, allowing for faster drug repurposing and insightful diagnostics.

AI’s Limitations and the Need for Human Expertise

Despite the evident benefits of AI in sorting and analyzing data, Adarsh Subbaswamy, PhD, cautions against fully delegating decision-making to machines. His insights stress the irreplaceable value of human judgment and expertise, particularly in understanding the context behind AI-driven recommendations. The partnership of AI capabilities with human oversight is crucial for ensuring responsible and effective drug development practices.

Innovative Educational Approaches

The uniqueness of UMSOP’s AIDD program lies in its educational philosophy. Rather than focusing purely on programming skills, the curriculum stands out by integrating AI with essential knowledge of drug development. This ensures that students are not just proficient in AI technologies but also possess the requisite industry insights to apply these technologies effectively.

Industry Insights Integrated into Learning

Joe Fitzgerald, a professional with nearly three decades in the pharmaceutical industry, highlights the program’s practical orientation. Every course is designed to interlink AI methodologies with real-world applications in drug portfolios, promoting deeper comprehension of the complete drug development lifecycle. By equipping professionals like Fitzgerald with dual competencies in AI and drug development, UMSOP effectively prepares a new generation of pharmacists and developers for the challenges posed by the evolving landscape of healthcare.